EE129 Cost-Effectiveness of Ofatumumab Versus Ocrelizumab in Patients With Active Relapsing Multiple Sclerosis in Portugal
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.381
https://www.valueinhealthjournal.com/article/S1098-3015(22)02585-2/fulltext
Title :
EE129 Cost-Effectiveness of Ofatumumab Versus Ocrelizumab in Patients With Active Relapsing Multiple Sclerosis in Portugal
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02585-2&doi=10.1016/j.jval.2022.09.381
First page :
Section Title :
Open access? :
No
Section Order :
12186